Dr. Michael J. Rogers at Garvan Institute of Medical Research, Australia recently published a research article on the high impact journal Cancer Discovery, using BioVinc’s imaging probes. Prof. Dr. Julie A. Sterling at the Vanderbilt University commented that “these findings are a critical first step to better understanding how BPs can be used as an adjuvant therapy for patients with primary disease who are at high risk for developing bone metastatic disease.

BioVinc is now pleased to offer a special discount for any similar and follow-up work which will use our products. Please contact us for more details (inquiry@biovinc.net).

Related publications:

  1. Real-Time Intravital Imaging Establishes Tumor-Associated Macrophages as the Extraskeletal Target of Bisphosphonate Action in Cancer. Junankar S, Shay G, Jurczyluk J, Ali N, Down J, Pocock N, Parker A, Nguyen A, Sun S, Kashemirov B, McKenna CE, Croucher PI, Swarbrick A, Weilbaecher K, Phan TG, Rogers MJ. Cancer discovery. 2015; 5(1): 35-42.
  2. Addressing the Controversy: Do Bisphosphonates Directly Affect Primary Tumors? Julie A. Sterling. Cancer Discovery. 2015; 5(1):14-15.